Akebia Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 14, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 14, 2024

AKBA$0.54+1.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ (Deficit) Equity

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders'(Deficit) Equity
(dollars in thousands) · Shares · Amount
Balance at December 31, 2021	177,000,963	$1	$1,536,800	$6	$(1,462,799)	$74,008
Issuance of common stock, net of issuance costs	4,404,600	1	7,121	—	—	7,122
Proceeds from sale of stock under employee stock purchase plan	335,146	—	410	—	—	410
Stock-based compensation expense	—	—	17,849	—	—	17,849
Restricted stock unit vesting	2,252,565	—	—	—	—	—
Exercise of options	142,440	—	67	—	—	67
Net loss	—	—	—	—	(94,226)	(94,226)
Balance at December 31, 2022	184,135,714	$2	$1,562,247	$6	$(1,557,025)	$5,230
Issuance of common stock, net of issuance costs	6,189,974	—	6,708	—	—	6,708
Proceeds from sale of stock under employee stock purchase plan	200,194	—	85	—	—	85
Stock-based compensation expense	—	—	9,317	—	—	9,317
Restricted stock unit vesting	4,054,407	—	—	—	—	—
Exercise of options	2,250	—	1	—	—	1
Net loss	—	—	—	—	(51,925)	(51,925)
Balance at December 31, 2023	194,582,539	$2	$1,578,358	$6	$(1,608,950)	$(30,584)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.